Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) (NCT05638295)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-E5 based on the presence of an actionable mutation as defined in EAY191
2. Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration/randomization to the EAY191-E5 study
3. Patient must be \>= 18 years of age
4. Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment
5. Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191-E5)
6. NOTE: The current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website: www.ctsu.org (final URL pending)
7. NOTE: Novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH registration protocol
8. Patient must have cytologically/histologically confirmed advanced/metastatic solid tumor
9. Patient must have progressed on at least one line of standard of care therapy in the advanced/metastatic setting
10. NOTE: Patients who have progressed on a prior human epidermal growth factor receptor (EGFR) inhibitor will meet this criterion
11. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 (or Karnofsky performance status \>= 60%)
12. Patient must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) documented by imaging obtained within 28 days prior to registration/randomization

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (180 Sites)

• University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
• University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
• The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California
• Cedars-Sinai Medical Center — Los Angeles, California
• VA Palo Alto Health Care System — Palo Alto, California
• UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
• UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
• UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
• UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
• UM Sylvester Comprehensive Cancer Center at Hollywood — Hollywood, Florida
• Mayo Clinic in Florida — Jacksonville, Florida
• University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
• UM Sylvester Comprehensive Cancer Center at Kendall — Miami, Florida
• UM Sylvester Comprehensive Cancer Center at Plantation — Plantation, Florida
• Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
• Saint Luke's Cancer Institute - Boise — Boise, Idaho
• Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
• Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
• Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
• Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
• Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
• Saint Luke's Cancer Institute - Nampa — Nampa, Idaho
• Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
• Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho
• Advocate Good Shepherd Hospital — Barrington, Illinois

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.